Slow traction clouding GSK-Dr Reddy's expansive deal?
This article was originally published in Scrip
Executive Summary
The landmark 2009 deal between GlaxoSmithKline and India's Dr Reddy's to sell branded generic formulations in emerging markets is under serious review. While efforts are underway to redefine a future path and co-operate in a few areas, sources suggest a termination may be among the options being considered.